| 00:00 | Symposium: Lessons Learned about COVID-19 |
| 105.4 |
Immunogenetics (HLA and ABO) Lori Jeanne West, Canada |
| 105.6 |
Global Impact of COVID-19 on Transplantation Alexandre Loupy, France |
| 105.1 |
Virology, Epidemiology and Clinical Course Olivia S. Kates, United States |
| 105.2 |
Organ Specific Involvement of COVID-19 Aneesha Anand Shetty, United States |
| 105.3 |
Diagnostics: PCR, Antigen Detection and Serology Robin Patel, United States |
| 105.5 |
Therapeutics & Vaccines Michael G. Ison, United States |
| 00:00 | Symposium: Transplanting in the Era of COVID-19 |
| 110.2 |
When a Recipient with COVID-19 Can Proceed to Transplant Paolo Antonio Grossi, Italy |
| 110.1 |
Donor Screening and the Risk of Virus Transmission Thomas D. Mone, United States |
| 110.4 |
Transplantation in the Hot Zone Jean C. Emond, United States |
| 110.3 |
Lung Transplantation for COVID-19 Jingyu Chen, People's Republic of China |
| 110.5 |
Transplantation and Ethical Issues in the COVID Era: Doing the right thing depends on location, resources and disease burden Peter G. Stock, United States |
| 22:00 - 23:30 | Workshop Session: Design of Xenotransplantation Clinical Trials |
| 201.1 |
Cornea Chang Ho Yoon, Korea |
| 201.2 |
Naked islets Kwang-Won Kim, Korea |
| 201.3 |
Encapsulated islets Shinichi Matsumoto, Japan |
| 201.4 |
Kidney Alfred Joseph Tector, United States |
| 00:15 - 02:00 | State-of-the-Art Session: Expanding the Donor Pool, Pushing the Limits |
| 222.2 |
Use of DCD organs in heart and lung transplant Gregory I Snell, Australia |
| 222.1 |
Use of HCV positive organs into HCV negative recipients David Goldberg, United States |
| 222.3 |
Transplant outcomes from older donors > Age 60 Colleen L. Jay, United States |
| 00:15 - 02:00 | State-of-the-Art Session: Inhaling the Evidence (Lung) |
| 223.1 |
Increasing allograft utilization and redefining marginality (to include discussion on Hep C, ischaemic time and Ex-situ perfusion) Alejandro Mario Bertolotti, Argentina |
| 223.3 |
Survivorship in lung transplantation (there is a constant need to reinforce that the surgical component alone is only a small step in the transplant process) Hilary J. Goldberg, United States |
| 08:15 - 10:00 | State-of-the-Art Session: Managing Immunosuppression When Things Go Wrong |
| 261.1 |
Managing IS in recipients with a failing graft Sangho Lee, Korea |
| 261.3 |
Managing IS in recipients treated for malignancies Daniel Seron, Spain |
| 261.2 |
Managing IS in recipients with complex infections Peter Chin-Hong, United States |
| 13:00 - 14:30 | Workshop Session: What is the Ideal Pig for Xenotransplantation? / Carl-Gustav Groth Xeno Prize |
| 276.1 |
Are remaining xeno-antigens relevant? Alfred Joseph Tector, United States |
| 276.2 |
The ideal modified pig, how many genes are necessary? Eckhard Wolf, Germany |
| 276.3 |
Do we need to address p?hysiologic incompatibilities David K. C. Cooper, United States |
| 276.4 |
Xeno-organ growth: myth or reality? Matthias Längin, Germany |
| 276.5 |
Presentation of the Carl-Gustav Groth Xeno Prize to Joachim Hundrieser Agnes Azimzadeh, United States |
| 22:00 - 23:30 | Workshop Session: What the ID Doc should know about … |
| 302.4 |
Rejection in intestinal transplant Gabriel E. Gondolesi, Argentina |
| 302.1 |
CLAD Gregory I Snell, Australia |
| 302.2 |
Bilomas Prema Raj Jeyaraj, Singapore |
| 302.3 |
Delayed allograft function after renal transplant Roslyn B Mannon, United States |
| 00:15 - 02:00 | State-of-the-Art Session: Metrics for OPO Performance in Organ Donation |
| 321.1 |
Utilizing administrative data sets to measure OPO performance Ryutaro Hirose, United States |
| 321.2 |
Performance measures around the world Jeremy Chapman, Australia |
| 321.3 |
Measurements of OPO performance utilizing death record audits in Australia Helen Opdam, Australia |
| 00:15 - 02:00 | Workshop Session: Sex in the Time of SARS-CoV-2 – Relevance to transplantation |
| 323.1 |
Sex, gender, and their impact on COVID 19 Deborah Clegg, United States |
| 323.2 |
Sex mAtteRS-CoV-2 in Transplantation Ruth Sapir-Pichhadze, Canada |
| 323.3 |
Panelists Bethany J. Foster, Canada |
| Biff F. Palmer, United States |
| Amanda Vinson, Canada |
| 06:00 - 07:30 | Workshop Session: Regulation of Xenotransplantation |
| 341.4 |
Update on the Changsha Communiques Wayne J. Hawthorne, Australia |
| 341.2 |
Regulation in China Shaoping Deng, People's Republic of China |
| 341.1 |
Regulation in Korea Ivo Kwon, Korea |
| 341.3 |
Regulating Safety: what’s new? Linda Scobie, United Kingdom |
| 07:30 - 08:15 | Oral Abstracts Session: Infectious Diseases |
| 353.5 (P-9.02 in Journal) |
Impact of non-active hepatitis B on patient survival after renal transplantation Marcel RG Naik, Germany |
| 353.2 |
A recent diagnosis of tuberculosis is a risk factor for post-transplant morbidity & mortality after liver transplantation: A propensity score match-based analysis Pradez Sapkota, India |
| 353.3 |
Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab Hyunwook Kwon, Korea |
| 353.4 |
Gram negative blood stream infection in renal transplant recipients: Risk factors and outcome from a transplant center in Pakistan Sunil Kumar Dodani, Pakistan |
| 08:15 - 10:00 | State-of-the-Art Session: The Salvage, the Extreme and the Beat Goes On (Heart) |
| 361.3 |
Surveillance strategies post heart transplantation (current evidence on biopsy vs imaging vs biomarkers) Peter S. Macdonald, Australia |
| 361.1 |
Options for bridging to transplantation (advanced HF management / home inotropes/ economic temporary bridging options / LV vent +/-ECMO ….etc) Anna Meyer, Germany |
| 361.2 |
Lessons from DCD heart transplantation Kumud K Dhital, India |
| 08:15 - 10:00 | Workshop Session: TTS-WTGF Joint Session: How to harness exercise post – transplantation (Impact) and how to measure patient reported outcomes in the Covid-19 Era |
| 363.1 |
Introduction and Welcome Chris Thomas, Australia |
| 363.6 |
Billion Steps Challenge 2: The Sequel – Using online exercise challenges to engage activity in transplant recipients Ka-Foon Chau, Hong Kong |
| 363.3 |
Refit for life (online rehabilitation program) as a way of delivering increased Qalys and outcomes Liz Schick, Switzerland |
| 363.2 |
Safety of various sports post transplant to dispel the myth of unacceptable risk in the context of Covid Paul Harden, United Kingdom |
| 363.4 |
Potential impact of exercise and sport on patient outcomes Gareth Wiltshire, United Kingdom |
| 363.5 |
Results of survey – Organ Transplant recipients health outcomes Zachary S. Brooks PhD, United States |
| 13:00 - 14:45 | Workshop Session: Global Strategies for Facilitating Ethical Practices in Organ Transplantation |
| 377.4 |
Developing programs in resource constrained areas – Vietnam Richard Allen, Australia |
| 377.3 |
Organ transplantation for refugees: The Latin American case Alejandro Niño Murcia, Colombia |
| 377.5 |
Combating paid donation in India Vivek Kute, India |
| 377.8 |
Strategies for increasing deceased donation in Iran Seyed Ali Malek Hosseini, Iran (Islamic Republic of) |
| 377.6 |
Combating paid donation in the Philippines Benita Padilla, Philippines |
| 377.1 |
Resident minorities Access to organ donation and transplantation – Middle-East Riadh Fadhil, Qatar |
| 377.2 |
Non-resident access to transplantation and impact on local lists – Europe Beatriz Domínguez-Gil, Spain |
| 377.7 |
Transplanting the undocumented in the USA Peter G. Stock, United States |
| 14:30 - 15:15 | Oral Abstracts Session: Stem Cell Transplantation and Xenotransplantation |
| 384.2 |
Quantifying the immune response to tissue engineered extracellular matrix Ryaan EL-Andari, Canada |
| 384.1 |
Simple Limbal Epithelial Transplantation (SLET) in a patient with limbal stem cell deficiency Dilek Dursun Altinors, Turkey |
| 384.3 |
Successful long-term TMA- and rejection-free survival of a kidney xenograft with triple xenoantigen knockout plus insertion of multiple human transgenes David Ma, United States |
| 15:15 - 17:00 | State-of-the-Art Session: How Sex Impacts Post-Transplant Course |
| 392.2 |
Sex differences in infection risks and vaccine responses Deepali Kumar, Canada |
| 392.1 |
Sex differences in cancer risk post-transplant Anna Buxeda, Spain |
| 392.3 |
Sex and the heart: Major cardiovascular events in transplantation Darshana Dadhania, United States |
| 22:00 - 23:30 | Workshop Session: TTS-ISHLT Joint Symposium: Capacity Building in Transplantation: Meeting Challenges Through Global Partnership |
| 402.3 |
Establishing ethical and legal standards – From organ trade to presumed consent Wendy Rogers, Australia |
| 402.4 |
Emerging programs - Dealing with the challenges of a global pandemic Saima Aslam, United States |
| 402.2 |
DCD in heart and lung transplantation – Is there a need for a global standard? Kumud K Dhital, India |
| 402.1 |
Collaborative models of organ allocation in an era of populism Howard J. Eisen, United States |
| 23:30 - 00:15 | Oral Abstracts Session: Heart and Lung Abstract Session |
| 413.1 |
Emerging roles of left ventricular assist device therapy as bridge to transplant in an Asian city with scarce heart transplant donor KA LAM WONG, Hong Kong |
| 413.3 (P-16.05 in the Journal) |
Does body size affect a successful bridge to heart transplantation by long-term continuous-flow ventricular assist device support? Minoru Ono, Japan |
| 413.4 |
Ambient air pollution and waitlist mortality among lung transplant candidates Mara McAdams DeMarco, United States |
| 00:15 - 02:00 | Workshop Session: Upcoming Issues in the Diagnosis of Transplant Rejection |
| 423.3 |
Dilemmas in renal allograft biopsy diagnosis Brian J Nankivell, Australia |
| 423.2 |
Gene expression in transplant tissue and body fluid Michael Mengel, Canada |
| 423.1 |
Digital pathology and machine learning in renal transplant pathology Alton "Brad" Farris, United States |
| 06:00 - 07:30 | Workshop Session: Unique Aspects of Organ Donation and Assessment in Pediatric Transplantation |
| 442.1 |
Risks for the living donor Michael Kaabak, Russian Federation |
| 442.2 |
Culture and religious perspectives Jun Oh, Germany |
| 442.4 |
ABO- and HLA- Incompatible transplantation Seiichiro Shishido, Japan |
| 442.3 |
Challenges of small paediatric donors Nam-Joon Yi, Korea |
| 08:15 - 10:00 | State-of-the-Art Session: Recent Breakthroughs in Xenogeneic Tissue and Organ Transplantation |
| 462.1 |
Heart Paolo Brenner, Germany |
| 462.3 |
Islets Chung-Gyu Park, Korea |
| 462.4 |
Cornea Mee Kum Kim, Korea |
| 462.2 |
Kidney Kazuhiko Yamada, United States |
| 08:15 - 10:00 | Workshop Session: Innovative Strategies for Eliminating Donor Financial Burdens |
| 463.1 |
Background : Economic impact, ethics, etc Jeremy Chapman, Australia |
| 463.2 |
Australian Perspective Henry Pleass, Australia |
| 463.3 |
European Perspective Paul Harden, United Kingdom |
| 463.4 |
Developing Country’s Perspective Ala Ali, Iraq |
| 463.5 |
US Perspective Deirdre Sawinski, United States |
| 13:00 - 14:30 | Workshop Session: CMV - What's New |
| 477.3 |
New risks for CMV in solid organ and stem cell transplant recipients José Maria Aguado, Spain |
| 477.1 |
New drugs against an old foe Francisco M Marty, United States |
| 477.2 |
Immune monitoring Camille Nelson Kotton, United States |
| 15:15 - 17:00 | State-of-the-Art Session: Paediatric Transplantation Around the World |
| 491.1 |
Paediatric kidney transplantation around the world Mignon McCulloch, South Africa |
| 491.2 |
Cost Effective Immunosuppressive Medications Around the World Katherine Twombley, United States |
| 491.3 |
Variety of vaccine preventive paediatric infectious diseases around the world Lara Danziger-Isakov, United States |
| Poster Session: Cellular and Regenerative Therapies |
| P-3.06 |
Generation of stable human induced regulatory T-cells requires optimal rapamycin concentration and TCR stimulation Juewan Kim, Australia |
| P-3.11 |
Small-for-size syndrome is characterized with PD-L1 upregulation in macrophage and blocking PD-L1 accelerates liver regeneration Ji-Hua Shi, People's Republic of China |
| P-3.14 |
Directed differentiation of iPS into imDCs under the action of SN can induce immunoreactivity in vitro Cuixiang Xu, People's Republic of China |
| P-3.15 |
Sinomenine enhances imDC derived from IPS cell-directed differentiation to induce transplant immune hyporesponsiveness in mouse Cuixiang Xu, People's Republic of China |
| P-3.03 |
Cell therapy using CD8+Tregs in human transplantation Séverine Bézie, France |
| P-3.10 |
Bile duct reconstruction using scaffold-free tubular constructs created by a Bio-3D Printer for transplantation Takashi Hamada, Japan |
| P-3.13 |
Visual rehabilitation after penetrating keratoplasty Leyla Asena, Turkey |
| P-3.16 |
Limbal stem cell transplantation for restoration of the ocular surface health in bilateral limbal stem cell deficiency Dilek Dursun Altinors, Turkey |
| P-3.01 |
Mass Cytometry Analysis of the Peripheral Regulatory T cell Compartment after Cellular Therapy in Renal Transplantation Alaa Alzhrani, United Kingdom |
| P-3.08 |
Successful induction of hematopoietic chimerism by MCL-1 and Bcl-2 inhibition without radiation/chemo therapy in nonhuman primates David Ma, United States |
| Poster Session: Donation and Procurement |
| P-4.03 |
Sharing of deceased donor livers in Australia and New Zealand Michael Fink, Australia |
| P-4.04 |
Removing the BMI bias in kidney transplantation: Outcomes of kidney transplantation in patients with BMI >35 Aaron YS Hui, Australia |
| P-4.05 |
Clinician perspectives on factors associated with delayed wait-listing for deceased donor renal transplantation in Australia Lachlan McMichael, Australia |
| P-4.10 |
Missed opportunities for organ donation from potential donors with primary brain tumours in Australia; cohort study 2010-2015 Imogen Thomson, Australia |
| P-4.12 |
Verification of suspected melanomas in deceased organ donor referrals: A population-based cohort study using data-linkage, 2010-2015 Brenda Marie Rosales, Australia |
| P-4.15 |
It’s not too late to donate...Controlled Donation after Circulatory Death (DCD) of lungs up to 24 hours after Withdrawal of Cardio Respiratory Support (WCRS) Katherine Labib, Australia |
| P-4.16 |
Perceived vs. verified risk of cancer transmission from deceased organ donors: a 2010-2015 cohort study using data linkage in New South Wales, Australia James A. Hedley, Australia |
| P-4.51 |
Kidney Paired Donation In Brazil Gustavo Fernandes Ferreira, Brazil |
| P-4.44 |
Health professional level barriers to living donor kidney transplantation: A mixed methods study Renata Iskander, Canada |
| P-4.11 |
A prediction model of delay graft function from deceased donor risk factor: A multi-center study from China Wujun Xue, People's Republic of China |
| P-4.23 |
Organ donation, a new subject developed in China towards professionalism Wenshi Jiang, People's Republic of China |
| P-4.61 |
Brain death-mediated inflammatory liver injury is mediated by hepatocytes apoptosis through TRAIL Zhong-kun Huo, People's Republic of China |
| P-4.35 |
Asymptomatic donor stones: Management algorithm Anant Kumar, India |
| P-4.24 |
Ten recommendations on approaching next of kin for consenting organ donation; Or How did we manage to increase consent rates by 64%? Omid Ghobadi, Iran (Islamic Republic of) |
| P-4.30 |
National implementation of Persian possible donor detection program: An 8-month efficiency evaluation Ali Etemadi, Iran (Islamic Republic of) |
| P-4.49 |
Minimum incision open donor nephrectomy versus laparoendoscopic single-site donor nephrectomy: A possible safe alternative Kentaro Ide, Japan |
| P-4.32 |
The meaning of kidney transplantation from circulatory death donor in local hospital Shin Do Suh, Korea |
| P-4.41 |
Predictors for renal outcome in living kidney donors: From data of Korean organ transplantation registry Yunmi Kim, Korea |
| P-4.48 |
Living liver donor surgical complication : Single center experience Eun-Kyoung Jwa, Korea |
| P-4.46 |
Laparoscopic left lateral sectionectomy in living liver donors: From the first experience to routine usage Konstantin O. Semash, Russian Federation |
| P-4.65 |
Does the cold storage really «cold»? Liver thermography and microdialysis findings Alexander I Sushkov, Russian Federation |
| P-4.19 |
Experiences with expanded criteria donors: 10-year analysis of the Martin, Slovakia Transplant Center Ivana Dedinska, Slovakia (Slovak Republic) |
| P-4.13 |
Impact of controlled donation after circulatory death (cDCD) on waiting list mortality for liver transplantation in the last 10 years: The Spanish experience Felipe Alconchel, Spain |
| P-4.22 |
ISO quality certification for a hospital-based organ procurement unit: The United Arab Emirates (UAE) experience María Paula Gómez, Spain |
| P-4.21 |
Deceased-donor transplantation activities in Turkey Ebru Hatice Ayvazoglu Soy, Turkey |
| P-4.08 |
Deceased kidney donor pre-procurement cardiac arrest associated with better long-term graft survival Shivani Bajpai, United States |
| P-4.18 |
Zero organ, one organ, and authorized-not recovered donors: Trends and opportunities in a growing organ procurement organization Jeffrey P. Orlowski, United States |
| P-4.47 |
Robotic versus open mini incision living donor nephrectomy: Single center experience Seung Duk Lee, United States |
| P-4.62 |
Bridging the gap: normothermic perfusion of discarded livers significantly alleviates the donor shortage in the United States Siavash Raigani, United States |
| P-4.84 |
Implementation of a national organ matching and data system for Australian solid organ transplantation programs Rhonda Holdsworth, Australia |
| P-4.100 |
Burnout and resilience among organ donation coordinators: A scoping review Vanessa Silva e Silva, Canada |
| P-4.102 |
Bric study - Burnout and resiliency levels among organ donation coordinators: Research protocol Vanessa Silva e Silva, Canada |
| P-4.69 |
Double-lobectomy in rat model of steatotic liver transplantation Fu Zhen, People's Republic of China |
| P-4.73 |
Value of CTGF in assessment of liver graft with non-alcoholic fatty liver disease after brain death Dongjing Yang, People's Republic of China |
| P-4.96 |
Tetramethylpyrazine activated PPARγ in resuscitating the liver graft donated after cardiac death Fu Zhen, People's Republic of China |
| P-4.111 |
Enabling legal provisions and their crucial role in promoting organ donation and transplantation – The Indian scenario Vasanthi Ramesh M.S., FALS, India |
| P-4.70 |
Lessons learned from perfusate analysis during dual hypothermic oxygenated machine perfusion of liver grafts Damiano Patrono, Italy |
| P-4.107 |
Deceased donor tissue recovery activity in Eastern Japan Sayaka Nagashima, Japan |
| P-4.101 |
Causes of lowered family consent rate for organ donation Eunsuk Yu, Korea |
| P-4.87 |
Brain death donation improvement areas: Procurement impact Olga E Facio, Mexico |
| P-4.74 |
Observations on 24-hour ex situ normothermic liver perfusion Amelia J Hessheimer, Spain |
| P-4.80 |
New technique for abdominal wall retrieval: Our initial outcomes with the new technique in non-vascularized fascia Iago Justo Alonso, Spain |
| P-4.81 |
Quorum: IT tool for organ donation quality system management: Pilot program in the Kingdom of Saudi Arabia Estephan Arredondo, Spain |
| P-4.82 |
Implementation results of the first hospital-based organ procurement unit in Kerala (India) María Paula Gómez, Spain |
| P-4.92 |
Protocol based on hepatitis C virus nucleic acid testing to optimize renal transplant from seropositive donors to seronegative recipients. An European experience antonio franco, Spain |
| P-4.98 |
International Registry In Organ Donation and Transplantation (IRODAT) – 2019 worldwide data María Paula Gómez, Spain |
| P-4.99 |
Heart transplantation from controlled donors: First case report in Spain ALONSO MATEOS RODRIGUEZ, Spain |
| P-4.83 |
Readiness of the retrieval team for deceased donor kidney transplantation in Thailand Korntip Phonphok, Thailand |
| P-4.94 |
Evaluation of one year, five years and ten years life time of patients with kidney transplant: Single-center experience Mehmet Fethullah Aydin, Turkey |
| P-4.110 |
Establishment of solid organ transplantation in the United Arab Emirates Shiva Kumar, United Arab Emirates |
| P-4.112 |
Establishment of liver transplantation in the United Arab Emirates from deceased and living donors Shiva Kumar, United Arab Emirates |
| P-4.66 |
Real-time viability assessment during normothermic machine perfusion with Raman spectroscopy Reinier de Vries, United States |
| P-4.76 |
Using pulsatile perfusion to successfully transplant kidneys with 15 percent glomerulosclerosis Marty T Sellers, United States |
| P-4.77 |
Deceased donor organ flush with equivalent volumes of HTK and UW at a single U.S. organ procurement organization Richard S. Mangus, United States |
| P-4.79 |
Automated electronic referrals are changing donation Wade Liu, United States |
| P-4.89 |
Salvaging discarded livers with normothermic machine perfusion: Is it worth the cost? Reinier de Vries, United States |
| P-4.95 |
Liver transplantation of hepatitis C-viremic donors to hepatitis C naive recipients Fidel Lopez-Verdugo, United States |
| P-4.97 |
Aggressive pursuit of liver only donors and their transplant outcomes: Should we continue? Marty T Sellers, United States |
| P-4.109 |
Pancreas transplant in chronic kidney disease for type 1 diabetic patients Rashikh A Choudhury, United States |
| P-4.85 |
Robotic versus laparoscopic living donor nephrectomy: A prospective study Thanh-Tuan Nguyen, Viet Nam |
| Poster Session: Thoracic (Heart and Lung) |
| P-16.24 |
Outcomes following extracorporeal photopheresis for chronic lung allograft dysfunction following lung transplantation: A single centre experience Jaideep Vazirani, Australia |
| P-16.27 |
Scedosporium apiospermum and lomentospora prolificans in lung transplant patients: A single centre experience over 24 years Jaideep Vazirani, Australia |
| P-16.11 |
Cancer risk in heart or lung transplant recipients: a meta-analysis Fan Ge, People's Republic of China |
| P-16.06 |
Long-term results of everolimus on renal function and rejection after heart transplantation in a real-life scenario Markus J. Barten, Germany |
| P-16.09 |
Left ventricular assist device explantation after cardiac recovery Christian Heim, Germany |
| P-16.16 |
Optimal dosing of cyclosporine and tacrolimus to improve medication adherence and to reduce drug costs after heart transplantation Markus J. Barten, Germany |
| P-16.13 |
Transplantation of heart-valve and vascular allografts for cardiovascular surgery: Retrospective analysis of the tissue bank registry data for more than 20 years Akihiro Masuzawa, Japan |
| P-16.17 |
Usefulness of basiliximab use for long waiting heart transplant recipients Noriko Kikuchi, Japan |
| P-16.23 |
Successful lung and liver co-transplantation in pediatric patient with dyskeratosis congenita SAMINA PARK, Korea |
| P-16.15 |
Infectious complications early-term after heart transplantation Maria Simonenko, Russian Federation |
| P-16.10 |
Combined heart-liver transplantation: Single center experience Amit Sharma, United States |
| P-16.18 |
Combined heart-kidney transplantation: single center experience Amit Sharma, United States |
| P-16.26 |
Pregnancy outcomes in 36 lung transplant recipients Lisa Coscia, United States |
| P-16.25 |
Lung transplant programs in developing countries: challenges and solutions Anh T Nguyen, Viet Nam |
| P-16.28 |
Lung transplantation during the outbreak of Coronavirus disease 2019: Early experience from China Jingyu Chen, People's Republic of China |
| P-16.30 |
Long-term diagnostic analysis of invasive pulmonary aspergillosis after solid organ transplantation: Spectrum of initial and follow-up CT findings Omer Koray Hekimoglu, Turkey |
